Compare LEA & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEA | IMVT |
|---|---|---|
| Founded | 1917 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.8B |
| IPO Year | 1994 | 2019 |
| Metric | LEA | IMVT |
|---|---|---|
| Price | $137.61 | $28.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $132.21 | $33.00 |
| AVG Volume (30 Days) | 530.0K | ★ 1.5M |
| Earning Date | 05-01-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.34 | N/A |
| Revenue | ★ $23,259,100,000.00 | N/A |
| Revenue This Year | $2.50 | N/A |
| Revenue Next Year | $3.12 | N/A |
| P/E Ratio | $41.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $86.14 | $13.52 |
| 52 Week High | $142.84 | $30.09 |
| Indicator | LEA | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 64.69 | 58.77 |
| Support Level | $115.63 | $24.97 |
| Resistance Level | $142.84 | $29.67 |
| Average True Range (ATR) | 4.46 | 1.48 |
| MACD | 1.16 | 0.01 |
| Stochastic Oscillator | 85.48 | 70.43 |
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.